USOR 24257 - Ph3 study of (Dato-Dxd) in subjects with met. Urothelial Carcinoma

A Randomized Open-Label Phase 2/3 Study of Datopotamab-Deruxtecan (Dato-DXd) plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Participants with Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) who Progressed during or After Enfortumab Vedotin (EV) plus Pembrolizumab Combination Treatment

Disease Types: Urothelial

Available at: Arlington Heights, Chicago Resurrection, Niles